Quarterly report pursuant to sections 13 or 15(d)

Commitments and Contingencies (Details 2)

v2.4.0.6
Commitments and Contingencies (Details 2) (Agreement to license intellectual property in exchange for payments, USD $)
0 Months Ended
Aug. 24, 2012
Agreement to license intellectual property in exchange for payments
 
Commitment and contingencies  
Payment upon start of future Phase II clinical trial $ 50,000
Payment upon start of future Phase III clinical trial 100,000
Payment upon FDA approval $ 250,000
Common stock agreed to issue (in shares) 150,000
Period to issue common stock within effective date of agreement 6 months